Peter Finan

Biography

Finan joined Epidarex Capital as a Venture Partner in 2014. He has more than twenty years of experience in drug discovery within the pharmaceutical industry. Prior to joining Epidarex, Dr. Finan was Global Head of the Respiratory Disease Area and Site Head for the Novartis Institute of BioMedical Research in the United Kingdom. In this role, Dr. Finan had strategic and operational oversight for the respiratory portfolio from target discovery through to proof-of-concept trials in the clinic. He is a former Executive Director of the Novartis Developmental and Molecular Pathways Platform based in Cambridge, Massachusetts were he led he initiation of the PI 3-kinase drug discovery program within Novartis and was awarded the Novartis Leading Scientist Award in 2007. Earlier in his career, Dr Finan worked at Cancer Research UK and the Yamanouchi Research Institute (now Astellas) and served as the Head of Biology at Karus Therapeutics Finan currently serves on the Board of Directors of Caldan Therapeutics Ltd., Clyde Biosciences Ltd., Enterprise Therapeutics Ltd., Mironid Ltd., and Topas Therapeutics GmbH. In addition to his role at Epidarex, Dr Finan is a Non-Executive Director at the Knowledge Transfer Network, a member of the Board of Directors and Scientific Advisory Board of the Keystone Symposia. Finan holds a BSc and Ph.D. in Biochemistry and Molecular Biology from the University of Leeds.

Research Interest

Biochemistry and Molecular Biology